Nitisinone-d3

Nitisinone-d3 (NTBC-d3) is deuterium labeled Nitisinone. Nitisinone is an orally active, competitive and reversible 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) inhibitor with an IC50 of 173 nM. Nitisinone promotes tyrosine accumulation in a dose-dependent manner. nitisinone can be used in studies of hereditary tyrosinemia type 1 (HT-1) (a rare genetic disorder) and albinism[1][2][3][4].

Product Specifications

Product Name Alternative

NTBC-d3; Nitisone-d3; SC0735-d3

UNSPSC

12352005

Target

HPPD; Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Smiles

O=C1C(C(C([2H])C([2H])C1[2H])=O)C(C2=CC=C(C=C2[N+]([O-])=O)C(F)(F)F)=O

Molecular Formula

C14H7D3F3NO5

Molecular Weight

332.25

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Laschi M, et al. Inhibition of para-Hydroxyphenylpyruvate Dioxygenase by Analogues of the Herbicide Nitisinone As a Strategy to Decrease Homogentisic Acid Levels, the Causative Agent of Alkaptonuria. ChemMedChem. 2016 Apr 5;11 (7) :674-8.|[3]Ellis MK, et al. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2- (2-nitro-4-trifluoromethylbenzoyl) -cyclohexane-1,3-dione and 2- (2-chloro-4-methanesulfonylbenzoyl) -cyclohexane-1,3-dione. Toxicol Appl Pharmacol. 1995 Jul;133 (1) :12-9. |[4]Onojafe IF, et al. Nitisinone improves eye and skin pigmentation defects in a mouse model of oculocutaneous albinism. J Clin Invest. 2011 Oct;121 (10) :3914-23. |[5]Aktuglu-Zeybek A, et al. Nitisinone: a review. Orphan Drugs: Research and Reviews, 2017, 7.